Aurobindo Pharma's subsidiary to acquire products from Spectrum Pharma
Singapore, Jan. 18 -- Aurobindo Pharma announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US.
Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which in turn a wholly-owned subsidiary of Aurobindo Pharma Limited, will be acquiring the portfolio on a debt free and cash free basis. This acquisition is in line with our strategy to commercialize innovative proprietary medications.
Commenting on the transaction, Dr. Ashish Anvekar, President of Acrotech, said: "We are excited to jump-start our mission of helping cancer patients acr...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.